Your browser doesn't support javascript.
loading
Risk of breakthrough infection and hospitalisation after COVID-19 primary vaccination by HIV status in four Italian regions during 2021.
Mateo-Urdiales, Alberto; Fabiani, Massimo; Mayer, Flavia; Sacco, Chiara; Belleudi, Valeria; Da Cas, Roberto; Fotakis, Emmanouil Alexandros; De Angelis, Luigi; Cutillo, Maria; Petrone, Daniele; Morciano, Cristina; Cannone, Andrea; Del Manso, Martina; Riccardo, Flavia; Bella, Antonino; Menniti-Ippolito, Franscesca; Pezzotti, Patrizio; Spila Alegiani, Stefania; Massari, Marco.
Afiliação
  • Mateo-Urdiales A; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy. Alberto.mateourdiales@iss.it.
  • Fabiani M; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Mayer F; National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy.
  • Sacco C; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Belleudi V; European Programme on Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control, Stockholm, Sweden.
  • Da Cas R; Department of Epidemiology, Lazio Regional Health Service, ASL Roma 1, Rome, Italy.
  • Fotakis EA; National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy.
  • De Angelis L; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Cutillo M; European Programme on Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control, Stockholm, Sweden.
  • Petrone D; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Morciano C; National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy.
  • Cannone A; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Del Manso M; National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy.
  • Riccardo F; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Bella A; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Menniti-Ippolito F; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Pezzotti P; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Spila Alegiani S; National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy.
  • Massari M; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
BMC Public Health ; 24(1): 1569, 2024 Jun 11.
Article em En | MEDLINE | ID: mdl-38862939
ABSTRACT

BACKGROUND:

As of 2024, vaccination remains the main mitigation measure against COVID-19, but there are contradictory results on whether people living with HIV (PLWH) are less protected by vaccines than people living without HIV (PLWoH). In this study we compared the risk of SARS-CoV-2 infection and COVID-19 hospitalisation following full vaccination in PLWH and PLWoH.

METHODS:

We linked data from the vaccination registry, the COVID-19 surveillance system and from healthcare/pharmacological registries in four Italian regions. We identified PLWH fully vaccinated (14 days post completion of the primary cycle) and matched them at a ratio of 14 with PLWoH by week of vaccine administration, age, sex, region of residence and comorbidities. Follow-up started on January 24, 2021, and lasted for a maximum of 234 days. We used the Kaplan-Meier estimator to calculate the cumulative incidence of infection and COVID-19 hospitalisation in both groups, and we compared risks using risk differences and ratios taking PLWoH as the reference group.

RESULTS:

We matched 42,771 PLWH with 171,084 PLWoH. The overall risk of breakthrough infection was similar in both groups with a rate ratio (RR) of 1.10 (95% confidence interval (CI)0.80-1.53). The absolute difference between groups at the end of the study period was 8.28 events per 10,000 person-days in the PLWH group (95%CI-18.43-40.29). There was a non-significant increase the risk of COVID-19 hospitalisation among PLWH (RR1.90; 95%CI0.93-3.32) which corresponds to 6.73 hospitalisations per 10,000 individuals (95%CI -0.57 to 14.87 per 10,000).

CONCLUSIONS:

Our findings suggest PLWH were not at increased risk of breakthrough SARS-CoV-2 infection or COVID-19 hospitalisation following a primary cycle of mRNA vaccination.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / Vacinas contra COVID-19 / COVID-19 / Hospitalização Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / Vacinas contra COVID-19 / COVID-19 / Hospitalização Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article